|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Tuberculosis is a major public health problem and second largest cause of death among infectious diseases. Rapid diagnosis of tuberculosis and detection of drug resistance is essential for effective disease control. WHO has endorsed the use of Line Probe assay (genotype MTBDR plus, Hain Life science) and the Xpert MTB/RIF assay (Cepheid, Sunnywale, USA) for rapid diagnosis of DRTB. The aim of this study is to know the prevalence of TB and its resistance pattern by using CBNAAT and LPA in Govt. General hospital, Kurnool. This is a prospective study done during the period from Jan 2016 to December 2016; all the samples were tested as per the RNTCP guidelines by using CBNAAT and LPA. Out of 1650 sputum samples, 280 (16.97%) were positive for Mycobacterium tuberculosis. Out of these, 18 (6.42%) showed Rifampicin (RIF) resistance by CBNAAT and 22 (7.8%) by LPA. Molecular technologies like LPA and Xpert MTB/RIF are the most promising technologies to detect drug resistance. The LPA test detects RIF due to mutation in rpoB gene as well as INH resistance due to mutations in the inhA and katG genes, while the Xpert MTB/RIF can detect only RIF resistance. In such cases LPA has greater role to play.